Results 21 to 30 of about 19,887 (300)

Direct-acting antivirals for chronic hepatitis C [PDF]

Cochrane Database of Systematic Reviews, 2016
Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response ...
Jakobsen, Janus C., Nielsen, Eric, Feinberg, Jesicca, Katakam, K, Fobian, K, Hauser, Goran, Poropat, Goran, Djurišić, Snežana, Weiss, K, Bjelaković, Milica, Bjelaković, Goran, Klingenberg, Sarah, Liu, J, Nikolova, Dimitrinka, Koretz, Ronald, Gluud, Christian   +15 more
openaire   +8 more sources

Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go

Pharmaceuticals, 2019
Zika virus (ZIKV) is a mosquito-borne flavivirus that spread throughout the American continent in 2015 causing considerable worldwide social and health alarm due to its association with ocular lesions and microcephaly in newborns, and Guillain−Barr&
Juan-Carlos Saiz
doaj   +1 more source

The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents [PDF]

African Journal of Gastroenterology and Hepatology, 2018
Background and aim Experts have reported thrombocytopenia is linked to chronic liver disease in up to 70% of patients with advanced fibrosis and portal hypertension. The occurrence of thrombotic thrombocytopenic purpura (TTP) with HCV infection is a rare
Amr Hanafy, Waseem Seleem, Salem Mohamed
doaj   +1 more source

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Viruses, 2021
The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...]
Anita Y.M. Howe, Francesca Ceccherini-Silberstein, Julia Dietz, Stephanie Popping, Jason Grebely, Chaturaka Rodrigo, Johan Lennerstrand, Mark W. Douglas, Milosz Parczewsk, P. Richard Harrigan, Jean-Michel Pawlotsky, Federico Garcia, SHARED Collaborators   +12 more
doaj   +1 more source

New horizons in hepatitis C antiviral therapy with direct-acting antivirals [PDF]

Hepatology, 2013
Abstract Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites ...
Alessio, Aghemo, Raffaele, De Francesco
openaire   +2 more sources

Therapeutic developments for SARS-CoV-2 infection—Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice

Frontiers in Microbiology, 2023
This article systematically presents the current clinically significant therapeutic developments for the treatment of COVID-19 by providing an in-depth review of molecular mechanisms of action for SARS-CoV-2 antivirals and critically analyzing the ...
Oana Săndulescu, Oana Săndulescu, Cătălin Gabriel Apostolescu, Cătălin Gabriel Apostolescu, Liliana Lucia Preoțescu, Liliana Lucia Preoțescu, Adrian Streinu-Cercel, Adrian Streinu-Cercel, Mihai Săndulescu   +8 more
doaj   +1 more source

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals [PDF]

Journal of Clinical and Translational Hepatology, 2016
Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade, resulting in better control of infection and clinical outcomes; however, drug-drug interactions remain a significant hazard. Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of ...
Rice, Donald P., Faragon, John J., Banks, Sarah, Chirch, Lisa M.   +3 more
openaire   +2 more sources

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study [PDF]

, 2019
An unexpected increased HCC recurrence and occurrence rate among HCV patients treated with direct acting antivirals combination has been reported. Aim of the study was the evaluation of early HCC occurrence rate and its risk factors in a HCV infected ...
De Luca, Massimo, Ciardiello, Fortunato, Coppola N., Ciardiello F., Guerrera, Barbara, Sasso, Ferdinando Carlo, Berretta M., Coppola, Nicola, Valente, Giovanna, Fasano M., Rinaldi, Luca, Nevola R., Izzi A., Izzi, Antonio, Monari, Caterina, Pafundi P. C., Valente G., Morisco F., Guerrera B., Guarino M., Monari C., Nevola, Riccardo, Piai G., Adinolfi, Luigi Elio, Martinelli E., Miglioresi, Lucia, Rinaldi L., Fasano, Morena, Perrella A., Miglioresi L., Berretta, Massimiliano, Pafundi, Pia Clara, Morisco, Filomena, Adinolfi L. E., Perrella, Alessandro, Sasso F. C., Guarino, Maria, Piai, Guido, Martinelli, Erika, De Luca M.   +39 more
core   +1 more source

Synergistic In Vitro Antiviral Effect of Combinations of Ivermectin, Essential Oils, and 18-(Phthalimid-2-yl)ferruginol against Arboviruses and Herpesvirus

Pharmaceuticals, 2023
Combining antiviral drugs with different mechanisms of action can help prevent the development of resistance by attacking the infectious agent through multiple pathways.
Liliana Betancur-Galvis, Orlando José Jimenez-Jarava, Fatima Rivas, William E. Mendoza-Hernández, Miguel A. González-Cardenete   +4 more
doaj   +1 more source

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype

Case Reports in Gastroenterology, 2015
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally
Tatsuo Kanda, Masato Nakamura, Reina Sasaki, Shin Yasui, Shingo Nakamoto, Yuki Haga, Xia Jiang, Shuang Wu, Akinobu Tawada, Makoto Arai, Fumio Imazeki, Osamu Yokosuka   +11 more
doaj   +1 more source